The year 2023 marked significant transformations in the medical and pharmaceutical sectors. Despite facing resistance from the medical community, President Yoon Suk Yeol's administration declared its intention to increase the number of medical school seats starting in 2025. Additionally, 2023 witnes
The Celltrion Group announced the launch of the integrated entity of Celltrion and Celltrion Healthcare, in which Celltrion will be absorbing Celltrion Healthcare to form a single entity, on Thursday.The scheduled date for the listing of new shares resulting from this merger is Jan. 12, 2024, and se
Medytox said it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for MT10109L, a non-animal-derived liquid botulinum toxin (BTX) formulation indicated for improving moderate to severe frown lines and crow's feet.The submission follows Medytox's completion
CHA Bundang Medical Center (CBMC) has reopened its expanded CHA Global Hospital to provide rapid and safe medical services for foreign patients.Located on the first floor of the main building of CBMC, the expanded CHA Global Hospital has improved convenience with dedicated consultation rooms and wai
In an extraordinary year for the Korean pharmaceutical and biotech industry, the sector has achieved a new milestone with 14 companies successfully finalizing 17 technology export deals, showcasing its growing global presence and innovative capabilities.The 14 companies include, Daewoong Pharmaceuti
VaxCell-Bio said it has signed a tripartite convergence business agreement with Jeonnam Bio Research Center (JBRC) and Thermo Fisher Scientific Solutions LLC to organically cooperate throughout the entire cycle to develop innovative cell therapy drugs.The main areas of cooperation include the exchan
Helixmith, a Korean biotech company, is set to change its largest shareholder from CanariaBio M to Biosolution Co.According to a public filing by Helixmith on Thursday, Helixmith's board meeting entered into a management rights transfer contract with Biosolution, including a paid-in capital increase
The Korean ankylosing spondylitis treatment market is at a significant turning point thanks to the expansion of health insurance benefits for related drugs, an expert said. Ankylosing spondylitis, if left untreated, can lead to a hunched back and stiff neck. Typically, the disease begins with altern
Myongji Hospital said it will join forces with Goyang City to support its goal of being designated as a "National Advanced Bio Strategy Industrial Specialized Zone" by utilizing its specialized technologies and medical infrastructure.The two institutions signed a memorandum of understanding (MoU) on
Bristol Myer Squibb (BMS)’s Camzyos has emerged as a groundbreaking treatment for obstructive hypertrophic cardiomyopathy (oHCM), a rare disease in which the muscle in the pumping chamber of the heart becomes thickened, an expert said in an interview with Korea Biomedical Review. Until now, the only
Osstem Implant, a Korean dental equipment manufacturer, said it may establish a dental medical equipment production facility in Saudi Arabia.The company announced that it had signed a memorandum of understanding (MoU) with the National Industrial Development Center under the Ministry of Industry and
In a heartwarming holiday tale, a young boy from Kyrgyzstan, previously living in seclusion due to severe facial burns, has undergone a successful facial reconstruction in Korea, thanks to a team of dedicated medical professionals from Asan Medical Center (AMC).According to AMC, Alinur, an eight-yea
Yongin Severance Hospital said the Indonesian Private Hospital Association, Asosiasi Rumah Sakit Swasta Indonesia (ARSSI), visited the Korean hospital to learn from its leadership in the smart hospital field.ARSSI, established in 2000 to nurture competitive hospitals in Indonesia, consists of 35 bra
HLB, a Kosdaq-listed anticancer drug developer, said that the combination of the targeted therapy rivoceranib and immunotherapy camrelizumab has proved effective not only in hepatocellular carcinoma (HCC) but also in lung cancer in a phase 2 clinical trial.HLB reported that Jiangsu Hengrui Pharmaceu
Gilead Sciences Korea said it has signed a memorandum of understanding to designate two Korean hospitals -- Seoul National University Hospital (SNUH) and Samsung Medical Center (SMC) – as Gilead HOPE (Hematology-Oncology Portfolio Engagement Site) institutions to collaborate on developing new oncolo
The Ministry of Food and Drug Safety (MFDS) said it imposed an administrative penalty equivalent to a 1.5-month suspension of clinical trials on Samsung Bioepis for violating regulatory requirements in conducting a clinical study.The clinical trial, "SB15-3001," was aimed to compare the efficacy, sa
C&C Research Labs, a subsidiary of JW Pharmaceutical, and XtalPi, a U.S.-based artificial intelligence drug development company, said they will cooperate in developing small molecule therapeutics, focusing on targeting the STAT6 protein, a key player in inflammatory immune responses.XtalPi, founded
SAN DIEGO, Calif. – By Lee Han-soo/Korea Biomedical Review correspondent -- A new study on the treatment of Extranodal NK/T-cell lymphoma (ENKTL) using a combination of isatuximab and cemiplimab has shown promising results, as reported by Professor Kim Seok-jin at Samsung Medical Center during the A
SAN DIEGO, Calif. – By Lee Han-soo/Korea Biomedical Review correspondent -- A recent study presented at the American Society of Hematology (ASH) 2023 conference in San Diego has highlighted the potential benefits of combining AbbVie's epcoritamab and lenalidomide for patients with relapsed/refractor
SAN DIEGO, Calif. – By Lee Han-soo/Korea Biomedical Review correspondent -- Korean researchers have presented evidence that brings people a step closer to achieving the goal of treatment-free remission (TFR) in the treatment of chronic myeloid leukemia (CML). Capturing significant attention, the res